113 related articles for article (PubMed ID: 36300981)
21. T cell immunity to SARS-CoV-2 following natural infection and vaccination.
DiPiazza AT; Graham BS; Ruckwardt TJ
Biochem Biophys Res Commun; 2021 Jan; 538():211-217. PubMed ID: 33190827
[TBL] [Abstract][Full Text] [Related]
22. Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids.
Chen KG; Park K; Spence JR
Nat Cell Biol; 2021 Aug; 23(8):822-833. PubMed ID: 34341531
[TBL] [Abstract][Full Text] [Related]
23. Pfizer COVID vaccine protects against worrying coronavirus variants.
Callaway E
Nature; 2021 May; 593(7859):325-326. PubMed ID: 33963317
[No Abstract] [Full Text] [Related]
24. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
25. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Spiera R; Jinich S; Jannat-Khah D
Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
[No Abstract] [Full Text] [Related]
26. Omicron likely to weaken COVID vaccine protection.
Callaway E
Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
[No Abstract] [Full Text] [Related]
27. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
28. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
29. Neutralizing SARS-CoV-2.
Poeschla E
Elife; 2020 Dec; 9():. PubMed ID: 33320086
[TBL] [Abstract][Full Text] [Related]
30. Case Builds for Booster Shots for People with Cancer.
Cancer Discov; 2022 Jan; 12(1):7. PubMed ID: 34764194
[TBL] [Abstract][Full Text] [Related]
31. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
[No Abstract] [Full Text] [Related]
32. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Volkan E
Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
[TBL] [Abstract][Full Text] [Related]
33. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
Front Immunol; 2021; 12():748103. PubMed ID: 34867974
[TBL] [Abstract][Full Text] [Related]
34. Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.
Vajo Z
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215791
[TBL] [Abstract][Full Text] [Related]
35. Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients.
Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Edwards ESJ; Brooks AES
Front Immunol; 2021; 12():798389. PubMed ID: 35116031
[No Abstract] [Full Text] [Related]
36. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
37. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
[No Abstract] [Full Text] [Related]
38. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike.
Crowley AR; Natarajan H; Hederman AP; Bobak CA; Weiner JA; Wieland-Alter W; Lee J; Bloch EM; Tobian AAR; Redd AD; Blankson JN; Wolf D; Goetghebuer T; Marchant A; Connor RI; Wright PF; Ackerman ME
Elife; 2022 Mar; 11():. PubMed ID: 35289271
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
40. Can immune responses predict which vaccines work best?
Cohen J
Science; 2021 Jul; 373(6551):142-143. PubMed ID: 34244387
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
